Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer.
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer.
复制标题
HER2-低表达在激素受体阳性早期乳腺癌中的预后影响。
DOI：
10.1016/j.breast.2021.08.016
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
Goldvaser H
中科院分区：
文献类型：
--
作者：
Mutai R;Barkan T;Moore A;Sarfaty M;Shochat T;Yerushalmi R;Stemmer SM;Goldvaser H
最近的数据表明，人表皮生长因子受体2（HER 2）-低乳腺癌可能代表一个独特的实体。我们的目的是比较雌激素受体（ER）阳性的早期乳腺癌中HER 2-low和HER 2 -0的疾病特征和结局。一项单中心回顾性研究，包括2005年至2012年期间进行Oncotype DX检测的所有ER阳性、HER 2阴性早期乳腺癌女性。将女性分为HER 2-低（免疫组织化学+1或+2，原位杂交未扩增）或HER 2 -0。收集临床病理特征和肿瘤型复发评分（RS）。根据HER 2表达状态评估总生存期（OS）、无病生存期（DFS）和无远处转移生存期（DDFS）数据。纳入608名女性，其中304名女性患有HER 2 -0，304名患有HER 2-低疾病。与HER 2低水平疾病相比，HER-0中小叶亚型显著更常见（17% vs. 8%，p = 0.005）。其他临床病理特征的患病率和长期预后在两组之间具有可比性。对于高基因组风险（RS > 25）的女性，HER 2低表达与显著有利的OS相关（HR = 0.31，95% CI 0.11-0.78，p = 0.01）、DFS（HR = 0.40，95% CI 0.20-0.82，p = 0.01）和DDFS（HR = 0.26，95% CI 0.11-0.63，P = 0.002）。对于低基因组风险（RS ≤ 25）的女性，长期预后与HER 2表达无关。HER 2-低表达对早期管腔疾病的预后影响因基因组风险而异，与高基因组风险女性中的HER 2 -0相比，HER 2-低表达的结局显著有利。HER 2阳性和HER 2阴性乳腺癌的二分分类受到了挑战。HER 2低表达的预后影响在Oncotype-DX风险组之间不同。与HER 2 -0相比，高风险（RS > 25）HER 2-低疾病与显著有利的结局相关。低基因组风险（RS < 25）HER 2-低与HER 2 -0的结局相似。这些新的发现可能指出了早期高基因组风险管腔疾病的新预后特征。
Recent data suggest that human epidermal growth factor receptor 2 (HER2)-low breast cancer may represent a distinct entity. We aimed to compare disease characteristics and outcomes between HER2-low and HER2-0 in estrogen receptor (ER) positive, early-stage breast cancer. A single center retrospective study comprising all women with ER positive, HER2 negative early breast cancer, for whom an Oncotype DX test was performed between 2005 and 2012. Women were grouped to HER2-low (immunohistochemistry +1 or +2 and in situ hybridization not amplified) or HER2-0. Clinico-pathological features and Oncotype recurrence score (RS) were collected. Data on overall-survival (OS), disease-free survival (DFS) and distant disease-free survival (DDFS) were evaluated according to HER2 expression status. 608 women were included, of which 304 women had HER2-0 and 304 had HER2-low disease. Lobular subtype was significantly more common in HER-0 compared to HER2-low disease (17% vs. 8%, p = 0.005). The prevalence of other clinic-pathological characteristics and long-term prognosis were comparable between both groups. For women with high genomic risk (RS > 25), HER2-low expression was associated with significantly favorable OS (HR = 0.31, 95% CI 0.11–0.78, p = 0.01), DFS (HR = 0.40, 95% CI 0.20–0.82, p = 0.01) and DDFS (HR = 0.26, 95% CI 0.11–0.63, P = 0.002) compared to women with HER2-0. For women with low genomic risk (RS ≤ 25), long-term prognosis was unrelated to HER2 expression. The prognostic impact of HER2-low expression in early-stage luminal disease varies across the genomic risk, with significant favorable outcomes of HER2-low expression compared to HER2-0 in women with high genomic risk. The dichotomous categorization of HER2-positive and HER2-negative breast cancer has been challenged. The prognostic impact of HER2-low expression differs between Oncotype-DX risk groups. High risk (RS > 25) HER2-low disease is associated with significantly favorable outcomes compared to HER2-0. Outcomes for low genomic risk (RS < 25) HER2-low vs. HER2-0 were similar. These novel findings may point on a new prognostic feature of early-stage, high genomic risk luminal disease.
登录
查看更多内容
DOI：
10.1097/pas.0b013e31819437f9
发表时间：
2009-05
期刊：
The American journal of surgical pathology
影响因子：
--
作者：
Gilcrease MZ;Woodward WA;Nicolas MM;Corley LJ;Fuller GN;Esteva FJ;Tucker SL;Buchholz TA
通讯作者：
Buchholz TA
影响因子：
45.3
作者：
Fehrenbacher, Louis;Cecchini, Reena S.;Wolmark, Norman
通讯作者：
Wolmark, Norman
影响因子：
6
作者：
Onsum, Matthew D.;Geretti, Elena;Hendriks, Bart S.
通讯作者：
Hendriks, Bart S.
影响因子：
45.3
作者：
Chirgwin, Jacquie H.;Giobbie-Hurder, Anita;Thurlimann, Beat
通讯作者：
Thurlimann, Beat
影响因子：
45.3
作者：
Hershman, Dawn L.;Kushi, Lawrence H.;Neugut, Alfred I.
通讯作者：
Neugut, Alfred I.